Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 20/20 | 1.00 |
| ▸ | CCND1 | P24385 | 20/20 | 1.00 |
| ▸ | CDK9 | P50750 | 20/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CDK2 | P24941 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23068004 | 1.00 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL29788720 | 1.00 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL29788700 | 1.00 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL29788692 | 0.95 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL23067979 | 0.95 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL23067986 | 0.94 | CCNT1 (0.90) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL29788730 | 0.93 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL23067950 | 0.93 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL29788670 | 0.93 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 | |
| SCHEMBL23081086 | 0.92 | CCNT1 (1.00) | CCNT1CDK4CCND1CDK9CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | claimed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | claimed |
| WO-2023056441-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-04-06 | — | — | WO | claimed |
| CN-114786673-A | CDK inhibitors and their use as medicaments | 普莱鲁德疗法有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | claimed |
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | Prelude Therapeutis Incorporated (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| WO-2023056441-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220324830-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-10-13 | — | — | US | disclosed |
| CN-114786673-A | CDK inhibitors and their use as medicaments | 普莱鲁德疗法有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4028005-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050824-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050824-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | CCNT1 40/4885CDK4 10/4885CCND1 47/4885 |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | CCNT1 40/4885CDK4 10/4885CCND1 47/4885 |
| US-20220324830-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | CCNT1 40/4885CDK4 10/4885CCND1 47/4885 |
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | CCNT1 40/4885CDK4 10/4885CCND1 47/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | CCNT1 40/4885CDK4 10/4885CCND1 47/4885 |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | CDK6, CDK3, CDK9 | CCNT1 40/4885CDK4 10/4885CCND1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.